Carl Balibar is a Principal Scientist in the department of Infectious Disease and Vaccines at Merck & Co. which he joined in 2012.

He is an expert in antibiotic mechanism of action and antibacterial drug discovery. He is specifically responsible for efforts ranging from early discovery and target validation through clinical development utilizing various modalities in support of anti-infective drug discovery.

Carl has written more than 30 papers and book chapters and participated in the discovery and development of the recently approved β-lactam/β-lactamase inhibitor combination imipenem/relebactam. For his doctoral research, he studied the biosynthesis of various biologically active natural products in the laboratory of Christopher T. Walsh. Carl joined the Novartis Institutes for BioMedical Research (NIBR) in 2007 as a postdoctoral fellow and subsequently became an investigator in the Infectious Diseases department working in the early discovery space to interrogate the physiology of various bacterial pathogens and discover novel antibacterial compound/target pairs.

Carl received his Bachelor of Science degree in Biology from Carnegie Mellon University and a PhD in Biological Chemistry and Molecular Pharmacology from Harvard University.